In an interview with Labiotech, Jacobs discussed the decisions behind Novavax’s transformation, the economics of its new ...

Explore the preclinical research catching our eye in October 2026, from AI drug design to small molecules and gene therapy ...

Three big bets in metabolic disease: the race to challenge Lilly and Novo, a pill that mimics exercise, and a gene therapy ...

Discover five myopia companies racing to go beyond glasses, as myopia is set to affect half the world by 2050.

Discover six companies advancing promising treatments for pulmonary hypertension beyond vasodilators, changing the standards of care.

Delve into the field of B7-H3 ADCs, a new contender in SCLC cancer, as Hansoh Pharma and Medilink bring momentum with ...

Delve into Labiotech's October oncology roundup and find out about the news that caught our attention this last month.

Learn when TIDE-based Sanger sequencing can replace NGS for measuring on-target gene editing efficiency in regulated ...

Join leading experts to explore practical strategies for designing and delivering rare disease clinical trials in Europe.

Discover Novo's pipeline in 2026, as it recently set out a new plan to reach $23 billion in risk-adjusted pipeline sales by ...

Accelerate@Babraham is a pre-seed biotech incubator in Europe, based at Babraham Research Campus in Cambridge. Its year-long program, which is offered to five early-stage startups annually, combines ...